ArticleCurrent drug targets2015
Proteomic Profiling of a Biomimetic Drug Delivery Platform.
Article in Current drug targets, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 38 citations in OpenAlex.
- Engineering of Glioblastoma-Derived Biomimetic Vesicles and Their Structural and Molecular Features.Advanced healthcare materials · 2026Article
- Nanoparticle-Based Interventions for Liver Transplantation.International journal of molecular sciences · 2023Review
- Biomimetic cell-derived nanocarriers in cancer research.Journal of nanobiotechnology · 2022Review
- Unleashing the potential of cell membrane-based nanoparticles for COVID-19 treatment and vaccination.Expert opinion on drug delivery · 2021Article
- Chemically Engineered Immune Cell-Derived Microrobots and Biomimetic Nanoparticles: Emerging Biodiagnostic and Therapeutic Tools.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Recent advances of biomimetic nano-systems in the diagnosis and treatment of tumor.Asian journal of pharmaceutical sciences · 2021Review
- Research Progress on Cell Membrane-Coated Biomimetic Delivery Systems.Frontiers in bioengineering and biotechnology · 2021Review
- Biomimetic Nanoparticles Potentiate the Anti-Inflammatory Properties of Dexamethasone and Reduce the Cytokine Storm Syndrome: An Additional Weapon against COVID-19?Nanomaterials (Basel, Switzerland) · 2020Article
- Bioinspired Extracellular Vesicles: Lessons Learned From Nature for Biomedicine and Bioengineering.Nanomaterials (Basel, Switzerland) · 2020Review
- Liposome-Embedding Silicon Microparticle for Oxaliplatin Delivery in Tumor Chemotherapy.Pharmaceutics · 2020Article
- Decoding communication patterns of the innate immune system by quantitative proteomics.Journal of leukocyte biology · 2019Review
- Cell membrane protein functionalization of nanoparticles as a new tumor-targeting strategy.Clinical and translational medicine · 2019Review
- Exosome-like Nanovectors for Drug Delivery in Cancer.Current medicinal chemistry · 2019Review
- Trends towards Biomimicry in Theranostics.Nanomaterials (Basel, Switzerland) · 2018Review
- Inflammation and Cancer: In Medio Stat Nano.Current medicinal chemistry · 2018Review
- Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.Seminars in immunology · 2017Review
- Post-nano strategies for drug delivery: Multistage porous silicon microvectors.Journal of materials chemistry. B · 2017Article
- Biomimetic carriers mimicking leukocyte plasma membrane to increase tumor vasculature permeability.Scientific reports · 2016Article
- Biomimetic proteolipid vesicles for targeting inflamed tissues.Nature materials · 2016Article
- The Emerging Role of Nanotechnology in Cell and Organ Transplantation.Transplantation · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Current delivery platforms are typically designed for prolonged circulation that favors superior accumulation of the payload in the targeted tissue. The design of efficient surface modifications determines both a longer circulation time and targeting abilities of particles. The optimization of synthesis protocols to efficiently combine targeting molecules and elements that allow for an increased circulation time can be challenging and almost impossible when several functional elements are needed. On the other hand, in the last decade, the development of bioinspired technologies was proposed as a new approach with which to increase particle safety, biocompatibility and targeting, while maintaining the synthesis protocols simple and reproducible. Recently, we developed a new drug delivery system inspired by the biology of immune cells called leukolike vector (LLV) and formed by a nanoporous silicon core and a shell derived from the leucocyte cell membrane. The goal of this study is to investigate the protein content of the LLV. Here we report the proteomic profiling of the LLV and demonstrate that our approach can be used to modify the surface of synthetic particles with more than 150 leukocyte membrane associated proteins that determine particle safety, circulation time and targeting abilities towards inflamed endothelium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.